鉴定与胃癌不良预后和肿瘤分期相关的关键基因。

Identification of key genes associated with poor prognosis and neoplasm staging in gastric cancer.

机构信息

Department of General Medicine, The First People's Hospital of Foshan, The Affiliated Foshan Hospital of Sun Yat-Sen University, Guangdong, China.

Second Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, GuangZhou, China.

出版信息

Medicine (Baltimore). 2023 Oct 6;102(40):e35111. doi: 10.1097/MD.0000000000035111.

DOI:10.1097/MD.0000000000035111

PMID:37800754

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10553055/

Abstract

BACKGROUND

Gastric cancer (GC) is highly biologically and genetically heterogeneous disease with poor prognosis. Increasing evidence indicates that biomarkers can serve as prediction and clinical intervention. Therefore, it is vital to identify core molecules and pathways participating in the development of GC.

METHODS

In this study, GSE54129, GSE56807, GSE63089, and GSE118916 were used for identified overlapped 75 DEGs. GO and Kyoto Encyclopedia of Genes and Genomes pathway analysis showed DEGs mainly enriched in biological process about collagen-containing extracellular matrix and collagen metabolic. Next, protein-protein interaction network was built and the hub gene was excavated. Clinicopathological features and prognostic value were also evaluated.

RESULTS

Hub genes were shown as below, FN1, COL1A2, COL1A1, COL3A1, COL4A1, COL6A3, COL5A2, SPARC, PDGFRB, COL12A1. Those genes were upregulation in GC and related to the poor prognosis (except COL5A2, P = .73). What is more, high expression indicated worse T stage and tumor, node, metastasis stage in GC patients. Later, the results of 25 GC tumor specimens and 34 normal tissues showed that FN1, COL3A1, COL4A1, SPARC, COL5A2, and COL12A1 were significantly upregulated in cancer samples.

CONCLUSION

Our study systematically explored the core genes and crucial pathways in GC, providing insights into clinical management and individual treatment.

摘要

背景

胃癌（GC）是一种高度具有生物学和遗传学异质性的疾病，预后较差。越来越多的证据表明，生物标志物可以作为预测和临床干预的指标。因此，确定参与 GC 发展的核心分子和途径至关重要。

方法

本研究使用 GSE54129、GSE56807、GSE63089 和 GSE118916 来鉴定 75 个重叠的 DEGs。GO 和京都基因与基因组百科全书通路分析显示，DEGs 主要富集在涉及含有胶原蛋白的细胞外基质和胶原蛋白代谢的生物学过程中。接下来，构建了蛋白质-蛋白质相互作用网络并挖掘了关键基因。还评估了临床病理特征和预后价值。

结果

关键基因如下：FN1、COL1A2、COL1A1、COL3A1、COL4A1、COL6A3、COL5A2、SPARC、PDGFRB、COL12A1。这些基因在 GC 中上调，并与不良预后相关（除 COL5A2，P=0.73）。此外，高表达表明 GC 患者的 T 分期和肿瘤分期、淋巴结转移和转移分期较差。随后，对 25 个 GC 肿瘤标本和 34 个正常组织的结果表明，FN1、COL3A1、COL4A1、SPARC、COL5A2 和 COL12A1 在癌症样本中显著上调。